Cairn Therapeutics
Targeting the Cancer, just the Cancer
Cancer is the leading cause of death. We want to change that.
Cairn Therapeutics’ research has been focused on making cancer treatment simpler and safer. As demonstrated in scientific studies, Cairn’s lead candidate, CT-262, shows the following:
- Exceptionally potent with dramatic efficacy not seen by other cytotoxics
- Broadly applicable to most solid tumor types as well as hematological tumors
- Designated for significantly better tolerability than any drug in its class: low toxicity, low myelosuppression that typically limits chemotherapy
- Not subject to traditional mechanisms of resistance
- A compelling replacement across a wide range of treatment regimens
